Please assess the completion status of the following clinical trial:

Trial Title: A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged ≥ 40 who have signed an Informed Consent Form prior to initiation of any study-related procedure.~* Subjects with a diagnosis of COPD (according to GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD Report) at least 12 months before the screening visit.~* Current smokers or ex-smokers who quit smoking at least 6 months prior to screening visit, with a smoking history of at least 10 pack years~* A post-bronchodilator forced expiratory volume in the 1st second (FEV1) ≥50% and \<80% of the predicted normal value and,~* a post-bronchodilator FEV1/ Forced Vital Capacity (FVC) \< 0.7 at screening and~* a demonstrated reversibility to ipratropium defined as ΔFEV1 ≥ 5% over baseline 30-45 minutes after inhaling 4 puffs of ipratropium~* Subjects under regular COPD therapy for at least 2 months prior to screening with either inhaled long-acting muscarinic antagonist (LAMA), inhaled ICS/ long-acting β2-agonist (LABA), inhaled ICS + LAMA~* Symptomatic subjects at screening with a CAT score ≥10. This criterion must be confirmed at randomization~* Symptomatic subjects with a BDI focal score ≤ 10. This criterion must be confirmed at randomization~* A cooperative attitude and ability to demonstrate correct use of the inhalers and e-diary.~Exclusion Criteria:~* Pregnant or lactating women and all women physiologically capable of becoming pregnant UNLESS they are willing to use highly effective birth control methods~* Diagnosis of asthma or Asthma-COPD Overlap Syndrome (ACOS) as described in global initiative for asthma (GINA) Report 2016, history of allergic rhinitis or atopy (atopy which may raise contra-indications or impact the efficacy of the study treatment according to Investigator's judgment)~* COPD Exacerbations: a moderate or severe COPD exacerbation that has not resolved ≤14 days prior to screening and ≤30 days following the last dose of any oral/systemic corticosteroid or antibiotic (whichever comes last). A Moderate or Severe COPD exacerbation during the run-in period~* Use of antibiotics for a lower respiratory tract infection in the 4 weeks prior to screening or during run-in~* Subjects treated with non-cardio-selective β-blockers in the month preceding screening or during the run-in period~* Subjects treated with long-acting anti-histamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study, or if taken as needed~* Subjects requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia~* Known respiratory disorders other than COPD which may impact the efficacy of the study treatment according the Investigator's judgment.~* Subjects who have clinically significant cardiovascular condition~* Subjects who have a clinically significant abnormal 12-lead ECG that results in active medical problem which may impact the safety of the subject according to Investigator's judgement~* Subjects whose 12-lead ECG shows Fridericia corrected QT interval (QTcF) \>450 ms for males or QTcF \>470 ms for females at screening visit~* Medical diagnosis of narrow-angle glaucoma, clinically relevant prostatic hypertrophy or bladder neck obstruction that in the opinion of the Investigator would prevent use of anticholinergic agents~* History of hypersensitivity to M3 receptor antagonists, β2-adrenergic receptor agonist, corticosteroids or any of the excipients contained in any of the formulations used in the study which may raise contra-indications or impact the efficacy of the study treatment according to the Investigator's judgement~* Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease which may impact the efficacy or the safety of the study treatment according to Investigator's judgement~* Subjects with serum potassium levels \<3.5 mEq/L (or 3.5 mmol/L) at screening~* Use of potent cytochrome P450 2D6 and 3A4 inhibitors within 4 weeks prior to screening~* Unstable or uncontrolled concurrent disease; fever, endocrine disease, gastrointestinal disease; neurological disease; hematological disease; autoimmune disorders, or other which may impact the feasibility of the results of the study according to Investigator's judgment~* History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening~* Subjects who have received an investigational drug within 1 month or 5 half-lives (whichever is greater) prior to screening visit, or have been previously randomized in this trial, or are currently participating in another clinical trial.~* Subjects who are mentally or legally incapacitated, or subjects accommodated in an establishment as a result of an official or judicial order.~* Subjects who have undergone major surgery in the 3 months prior to screening visit or have a planned surgery during the trial.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): CHF 5259 pMDI 6.25 μg, 1 inhalation twice daily (bid); (total daily dose \[TDD\] of CHF 5259 12.5 μg)
- Treatment B (Type: EXPERIMENTAL): CHF 5259 pMDI 12.5 μg, 1 inhalation bid; (TDD of CHF 5259: 25 μg)
- Treatment C (Type: EXPERIMENTAL): CHF 5259 pMDI 12.5 μg, 2 inhalations bid; (TDD of CHF 5259: 50 μg)
- Treatment D (Type: EXPERIMENTAL): CHF 5259 pMDI 25 μg, 2 inhalations bid; (TDD of CHF 5259: 100 μg)
- Treatment E (Type: PLACEBO_COMPARATOR): Placebo, 2 inhalations of CHF 5259 pMDI-matched Placebo bid;
- Treatment F (Type: ACTIVE_COMPARATOR): Tiotropium (TIO) 18 μg, SPIRIVA® HandiHaler®, 2 inhalations once daily (od) of the content of 1 capsule; (TDD of TIO: 18 μg)

Based on this trial design, predict the completion outcome and termination type (if applicable).